Alimera Sciences Announces Positive 36-Month Results From the Completed Phase 3 FAME(TM) Study of ILUVIEN(R) in Patients With Diabetic Macular Edema

ATLANTA, Feb. 3, 2011 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq:ALIM) ("Alimera"), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today reported results through month 36 of the completed FAME™ Study.